Gliflozin schützt Nieren und Herz bei Patienten mit diabetischem Nierenschaden

Weyrich P, Schätzle G, Maljkovic M, von Gersdorff G. Dialyse bei Diabetes. Dial Aktuell. 2018;22:225–9
Article Google Scholar
Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117–28
Article CAS Google Scholar
Neal B, Perkovic V, Mahaffey KW et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377:644–57
Article CAS Google Scholar
Anders HJ, Davis JM, Thurau K. Nephron Protection in Diabetic Kidney Disease. N Engl J Med. 2016;375(21):2096–8
Article Google Scholar

Originalie

Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; https://doi.org/10.1056/NEJMoa1811744
Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

Dr. Link / Prof. Dr. Weyrich, Hauptstraße 2, 82008, Unterhaching, Deutschland
Peter Weyrich (Ärztlicher Leiter KfH-Nierenzentrum, Nephrologische Gemeinschaftspraxis)

Authors

Peter Weyrich
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Weyrich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weyrich, P. Gliflozin schützt Nieren und Herz bei Patienten mit diabetischem Nierenschaden. Info Diabetol 13, 12–13 (2019). https://doi.org/10.1007/s15034-019-1500-z

Download citation

Published: 01 June 2019
Issue Date: June 2019
DOI: https://doi.org/10.1007/s15034-019-1500-z

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Gliflozin schützt Nieren und Herz bei Patienten mit diabetischem Nierenschaden

Access this article

Literatur